Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03442621 · ClinicalTrials.gov registry record · Phase 1
Relacorilant Food Effect Study in Healthy Subjects
A Phase 1 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03442621 is a Phase 1 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT03442621, a Phase 1 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is an open-label, randomized, single-dose, 3-period crossover, Williams' design, food-interaction (fasted and fed arms) study conducted in healthy subjects.
Interventions
- DRUG Relacorilant Fasted
- DRUG Relacorilant with a high fat breakfast
- DRUG Relacorilant with a moderate breakfast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-01-16 |
| Est. Completion | 2018-03-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03442621
The ClinicalTrials.gov registry entry for NCT03442621 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Relacorilant Fasted is the first listed.
NCT03442621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03442621 about?
NCT03442621 is a clinical study titled "Relacorilant Food Effect Study in Healthy Subjects". This is an open-label, randomized, single-dose, 3-period crossover, Williams' design, food-interaction (fasted and fed arms) study conducted in healthy subjects.
What is the current status of trial NCT03442621?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-01-16. Estimated completion is 2018-03-09.
What interventions are being tested in trial NCT03442621?
The interventions under investigation include: Relacorilant Fasted (DRUG), Relacorilant with a high fat breakfast (DRUG), Relacorilant with a moderate breakfast (DRUG).
Who is sponsoring clinical trial NCT03442621?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.